» Articles » PMID: 32082887

Comparison of Serum Biochemical Markers in Patients with Mesothelioma and Pleural Plaques Versus Healthy Individuals Exposed to Environmental Asbestos

Overview
Date 2020 Feb 22
PMID 32082887
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In this study, we aimed to compare serum biochemical markers in patients with malignant pleural mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos.

Methods: Between September 01, 2010 and March 31, 2011, a total of 540 participants (354 males, 186 females; mean age 61.4 years; range, 35 to 89 years) were included in the study. The participants were divided into four groups as follows: (1) patients with pleural plaques (n=277); (2) healthy individuals with normal chest X-rays who were exposed to environmental asbestos (n=121); (3) healthy individuals with normal chest X-rays who were not exposed to environmental asbestos (n=118); and (4) patients with malignant pleural mesothelioma (n=24). Serum levels of carcinoembryonic antigen, cancer antigen 125, 15-3, 19-9, free T3, free T4, thyroidstimulating hormone, vitamin B12, folate, and ferritin were measured.

Results: Serum cancer antigen 125, 15-3, folic acid, vitamin B12, and ferritin levels were higher with lower free T3 levels in Group 4 than the other groups. The areas under the curve for cancer antigen 125 and 15-3 were 0.78 and 0.67, respectively in the differential diagnosis of mesothelioma from other pathologies (p<0.001 for both). Optimal limits of these biomarkers were 13.63 and 18.43 ng/mL, respectively with 83% and 75% sensitivity and 69% and 48% specificity, respectively.

Conclusion: The combination or individual use of serum cancer antigen 125, 15-3, folic acid, vitamin B12, and ferritin levels may be helpful for early diagnosis and treatment of malignant pleural mesothelioma.

Citing Articles

Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis.

Schillebeeckx E, van Meerbeeck J, Lamote K Eur Respir Rev. 2021; 30(162).

PMID: 34789461 PMC: 9489015. DOI: 10.1183/16000617.0057-2021.


Biomarkers for Malignant Pleural Mesothelioma-A Novel View on Inflammation.

Vogl M, Rosenmayr A, Bohanes T, Scheed A, Brndiar M, Stubenberger E Cancers (Basel). 2021; 13(4).

PMID: 33562138 PMC: 7916017. DOI: 10.3390/cancers13040658.

References
1.
Pass H, Levin S, Harbut M, Melamed J, Chiriboga L, Donington J . Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012; 367(15):1417-27. PMC: 3761217. DOI: 10.1056/NEJMoa1115050. View

2.
Cristaudo A, Bonotti A, Guglielmi G, Fallahi P, Foddis R . Serum mesothelin and other biomarkers: what have we learned in the last decade?. J Thorac Dis. 2018; 10(Suppl 2):S353-S359. PMC: 5830556. DOI: 10.21037/jtd.2017.10.132. View

3.
Milman N, Moller Pedersen L . The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer. Oncol Rep. 2001; 9(1):193-8. View

4.
Portal J, Rodriguez Becerra E, Rodriguez Rodriguez D, Alfageme Michavila I, Quero Martinez A, Diego Roza C . Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev. 2009; 18(2):646-50. DOI: 10.1158/1055-9965.EPI-08-0422. View

5.
Bruno F, Baratti D, Martinetti A, Morelli D, Sottotetti E, Bonini C . Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. Eur J Surg Oncol. 2018; 44(6):792-798. DOI: 10.1016/j.ejso.2018.02.010. View